Running header: Progranulin haploinsufficiency induced cell cycle dysfunction in nonneuronal cells.
I N T R O D U C T I O N
Frontotemporal lobar degeneration (FTLD) is now a widely recognized form of dementia, characterized by gradual, progressive changes in behavior, personality and/or language with early preservation of memory (Ikeda et al., 2004) . It is responsible for at least 20% of presenil cases (Neary et al., 2000) . This heterogeneous disease has been of particular interest to geneticists due to its high rate of heritability with up to 40% of patients reporting a family history of the disease in at least one extra family member.
The main clinical presentations of FTLD are 1) behavioural bv-FTD, with disinhibition and changes in personality, such as apathy and poor judgment and 2) language, with a nonfluent aphasia with anomia (primary progressive aphasia, PPA), or a fluent aphasia with early loss of word meaning (semantic dementia, SD).
Pathologically, these diseases share deposits of abnormal proteins in neuroectodermic cells, and severe cell loss with atrophy of vulnerable cortical and subcortical structures (Mackenzie et al., 2006) . The most common pathology in FTLD, accounting for 40-65% of cases, has found to be neuritis, neuronal cytoplasmic inclusions, and lentiform intranuclear inclusions, containing as the major component the TAR DNA binding protein 43 (TDP-43) (Arai et al., 2006; Neumann et al., 2006) , and thus named FTLD-TDP (Mackenzie et al., 2010a) . Four different patterns of TDP-43 pathology are recognized in FTLD-TDP, based on the anatomical distribution, morphology, and relative proportion of distinct types of inclusions. (Mackenzie et al., 2010b ). This heterogeneity is also supported by different clinical and genetic features. The FTLD-TDP includes the behavioral variant FTD (bv-FTD), PPA and FTD with motor neuron disease (FTD-MND) (Bugiani, 2007) . The next largest group of FTLD cases comprises FTLD with taupositive pathology (FTLD-tau) (Kumar-Singh and Van Broeckhoven, 2007) , and these patients can present atypical parkinsonism in addition to bv-FTD and PPA. Recently another small group of cases has been described to be immunoreactive for FUS (FTLD-FUS) mutations of which have been associated with amyotrophic lateral sclerosis (ALS) (Kwiatkowski et al., 2009; Vance et al., 2009) . The overlap between ALS and FTD, as well as the homology of FUS and TDP-43 prompted a number of studies that demonstrated that the inclusions of the several tau/TDP-43 negative FTLDs were immunoreactive for FUS (Muñoz et al., 2009; Neuman et al. 2009 ), including the formerly designed FTLD-UPS because the inclusions were detected with antibodies anti proteins of the ubiquitin proteasome system (UPS) (Mackenzie et al., 2010a) .
Mutations in the progranulin gene (PGRN) have been identified as the major cause of FTLD-TDP (Baker et al., 2006; Cruts et al., 2006) . All cases of PGRN mutations are recognized as the subtype 1 of FTLD-TDP (Mackenzie et al., 2010b) , with most frequent presentations of bv-FTD and PPA (Mackenzie et al., 2010b) . Up to now more than 60 different mutations in PGRN have been described associated with the etiology of the disease (http://www.molgen.ua.ac.be/FTDmutations/) (Gijselinck et al., 2008) . We have recently described a prevalent ancestral c.709-1G>A mutation related to Basque population (Lopez de Munain et al., 2008; Moreno et al., 2009) . The c.709-1G>A mutation results in null allele, as most of the pathogenic mutation described up to now, suggesting that FTLD in these families results from PGRN haploinsufficiency (Baker et al., 2006) .
The biological functions of PGRN in the CNS have not been very well studied, and the mechanisms by which PGRN haploinsufficiency leads to neurodegeneration in FTLD remained speculative. PGRN is expressed in neurons and microglia (Ahmed et al., 2007) .
Some data suggests that PGRN may function as an autocrine neuronal growth factor. For instance, the addition of low concentrations of PGRN can promote mitogenesis in PC12 cells (Zhou et al., 1993) . In addition, a possible role for PGRN in CNS inflammation has been proposed (Ahmed et al., 2007; Eriksen and Mackenzie, 2008) . On these grounds, it seems plausible that neurodegeneration may result from reduced neuronal growth support or protection (Mackenzie, 2007; Neumann et al., 2007) .
Studies carried out during last decade have highlighted the important role that cell cycle dysfunction may play in the instigation and progression of neurodegeneration (Wishart et al., 2006) . Neuronal changes supporting alterations in cell cycle control in the etiology of neurodegenerative disorders include the ectopic expression of markers of the cell cycle, organelle kinesis, and DNA replication (Copani et al., 2001; Herrup et al., 2004; Zhu et al., 2004) . Aberrant induction of cell cycle regulators in postmitotic neurons have been Met tau mutation. These authors also reported changes in cell cycle regulatory proteins in other FTLD-tau diseases such as Corticobasal degeneration (CBD) or Pick disease (Husseman et al., 2000) A recent report has suggested a possible link between FTLD-TDP and altered cell cycle control (Ayala et al., 2008) . Loss of functional nuclear TDP-43 as the consequence of accumulation of the protein in cytoplasm, leads to increased cyclin/CDK activity and retinoblastoma protein phosphorylation (pRb), which is a major determinant for G 1 progression (Weinberg, 1995) .
The main goal of this work has been to study the influence of PGRN haploinsufficiency in cell cycle regulation of peripheral blood cells, which are easily accessible, from c.709-1G>A PGRN mutation carriers (PGRN+ cells). To this end, we have analyzed the proliferative activity of lymphoblasts from patients as well as from asymptomatic c.709-1G>A carriers and control subjects. Although FTLD symptoms reflect preferential neuronal loss in specific brain regions, PGRN is expressed in almost all tissues, so abnormalities outside the brain might be expected. In fact it is known that PGRN is highly expressed in peripheral blood cells (Coppola et al., 2008) and deficit of PGRN mRNA and/or protein levels, had been detected in lymphocytes from PGRN mutation carriers (Coppola et al., 2008; Finch et al., 2009; Lopez de Munain et al., 2008 (Wang et al., 1990) . EBV-immortalized lymphocytes retain the cellular response of fresh obtained lymphocytes, to serum addition or withdrawal. We found similar changes in cell proliferation and survival, as well as in the content of certain regulatory proteins, in these cell lines than untransformed lymphocytes (Bartolome et al., 2007; Munoz et al., 2008) , suggesting the usefulness of this experimental model particularly to study cell cycle-related events associated to DNA was extracted from blood cells using standard procedures. PGRN gene sequencing procedures used at our laboratory have been published elsewhere (Lopez de Munain et al., 2008) . For determination of progranulin plasma levels we used an ELISA kit (AdipoGene, Korea).
Establishment of lymphoblastic cell lines was performed in our laboratory as previously described (Ibarreta et al., 1998) by infecting peripheral blood lymphocytes with the Epstein Barr virus (EBV) (Koistinen, 1987) . Cells were grown in suspension in T flasks in an upright position, in approximately 10 ml of RPMI-1640 (Invitrogen) medium that contained 2 mM L-glutamine, 100 mg/ml penicillin/streptomycin and, unless otherwise stated, 10 % (v/v) fetal bovine serum (FBS) and maintained in a humidified 5% CO 2 incubator at 37 o C. Fluid was routinely changed every two days by removing the medium above the settled cells and replacing it with an equal volume of fresh medium.
Determination of cell proliferation
Proliferation was determined by cell counting in a Neubauer chamber. EBV immortalized lymphocytes from control and PGRN mutation carriers were seeded at an initial cell concentration of 1 x 10 6 cells x ml -1 . Cells were enumerated everyday thereafter. Potential toxicity of the reagents used was routinely checked by trypan blue exclusion under inverted phase-contrast microscopy.
C ell cycle analysis
Exponentially growing cultures of cell lines were seeded at an initial concentration of 1 x 10 6 cells x ml -1 . Cell cycle analysis was performed using a standard method (Krishan, 1975) . Cells were fixed in 75% ethanol for 1 h at room temperature. Subsequent centrifugation of the samples was followed by incubation of cells in PBS containing 1 mg/ml of RNase at room temperature for 20 min and staining with propidium iodide (PI; 25 mg/ml). Cells were analyzed in an EPICS-XL cytofluorimeter (Coulter Científica, Móstoles, Spain). Estimates of cell cycle phase distributions were obtained by computer analysis of DNA content distributions.
Immunological analysis C ell extracts
To prepare whole cell extracts, cells were harvested, washed in PBS and then lysed in ice-cold lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 50 mM NaF, 1% Nonidet P-40), containing 1 mM sodium orthovanadate, 1 mM PMSF, 1 mM sodium pyrophosphate and protease inhibitor Complete Mini Mixture (Roche, Mannhein).
Cytosolic and nuclear proteins were differentially extracted by lysing cells in ice-cold hypotonic buffer (10 mM Hepes, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT) containing 1 mM sodium orthovanadate, 1 mM PMSF, 1 mM sodium pyrophosphate, and protease inhibitor mixture. After extraction on ice for 15 min, 0.5 % Nonidet P-40 was added, and the lysed cells centrifuged at 4000 rpm for 10 min.
Supernatants containing cytosolic proteins were centrifuged at 13000 rpm for 10 min.
Nuclei were washed twice with the hypotonic buffer, and then lysed in hypertonic buffer (20 mM Hepes, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT) containing 1 mM sodium orthovanadate, 1 mM PMSF, 1 mM sodium pyrophosphate and protease inhibitor mixture. After extraction on ice for 30 min, the samples were centrifuged at 15000 rpm for 15 min at 4ºC. Antibodies to -tubulin and to lamin B1 were used to assess the purity of the fractions.
The protein content of the extracts was determined by the Bio-Rad protein assay kit (Bio-Rad Laboratories, Richmond, CA)
W estern blot analysis 50-100 g of protein from cell extracts were fractionated on a SDS polyacrylamide gel, and transferred to PVDF membrane (Immobilon-P). The amount of protein and the integrity of transfer were verified by staining with Ponceau-S solution (Sigma). The membranes were then blocked with non-fat milk and incubated, overnight at 4ºC, with primary antibodies at the following dilutions: 1:500 anti-pRb, 1:500 anti-CDK2, 1:500
anti-CDK4, 1:200 anti-CDK6, 1:500 anti cyclin E, 1:1000 anti cyclin D1, 1:100 anticyclin D2, 1:2000 anti-cyclin D3, 1:500 anti-p27, 1:500 anti-p21, 1:500 anti-p16, 1:200
anti-p18, 1:500 anti-TDP-43, 1:2000 -actin, and 1:1000 anti-lamin . Signals from the primary antibodies were amplified using species-specific antisera conjugated with horseradish peroxidase (Sigma) and detected with a chemiluminiscent substrate detection system ELC (Amersham). The relative protein levels were determined by scanning the bands with a GS-800 imaging densitometer provided with the Quantity One 4.3.1 software from BioRad.
Confocal laser scanning microscopy
Immortalyzed lymphocytes from control and c.709-1G>A carriers individuals were seeded at an initial density of 1 x 10 6 x ml -1 and incubated in RPMI medium containing 10% FBS for 48 h. 
Statistical analysis
Unless otherwise stated, all data represent means  standard error of the mean (SE).
Statistical analysis was performed on the Data Desk package (version 4.0) for Macintosh. Statistical significance was estimated by the Student's ttest or, when appropriated, by analysis of variance (ANOVA) followed by the Fischer's LSD test for multiple comparisons. Differences were considered significant at a level of p< 0.05.
R ESU L TS
Proliferative activity of lymphoblasts from control and PG R N+ individuals. Cell cycle disturbances in neurodegenerative disorders appear to involve a G 1 /S checkpoint failure (Nagy, 2007) . For this reason, we find it interesting to determine the cell cycle status of lymphoblasts from control or c.709-1G>A carriers, either asymptomatic or FTLD patients, after 36 h of serum stimulation. As shown in Fig. 2 , the proportion of cells in G1 phase was significantly lower and the proportion of cells in S phase was significantly higher in PGRN+ cells than those in control cells, 36 h after of serum stimulation. Again, no differences in cell cycle distribution were found between lymphoblasts from asymptomatic or FTLD patients (Fig. 2) . On the other hand we did not observed significant changes in the proportion of sub-G 0 /G 1 hypodiploid cells, characteristic of apoptosis/necrosis among the groups (Fig. 2) , suggesting that the increased cell number in cultures of c.709-1G>A carriers, truly reflects an increase in cell proliferation.
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E xpression of key cell cycle regulatory proteins in control and P G R N+ lymphoblasts.
Passage through the restriction point in late G 1 and commitment to DNA synthesis are controlled by the presence and phosphorylation status of pRb (Draetta, 1994; Weinberg, 1995) . Hypo-and hyperphosphorylated forms of this protein are easily distinguished in SDS-polyacrylamide gels. Fig. 3 shows the phosphorylation status of pRb in control and PGR+ lymphoblasts 48 h after serum stimulation. It is observed an increase in pRb phosphorylation in PGRN+ cells, as evidenced by the higher intensity of the slower migrating band (Fig. 3) .
The phosphorylation of pRb is mediated by the cyclin-dependent kinases CDK4/CDK6-cyclin D1 and CDK2-cyclin E (Lundberg and Weinberg, 1998; Mittnacht, 1998) . As shown in Fig. 4 no differences were observed in the protein levels of cyclins E, D2 and D3 between control or PGRN+ cells. The levels of cyclin D1 were barely detectable in these cell cultures (Fig. 4) . Fig 5 shows the cellular content of CDKs. While CDK2 and CDK4 levels were similar in control and PGRN+ lymphoblasts, we detected a significant increase in CDK6 was found in both PGRN+ cells from asymptomatic or FTLD patients (Fig. 5) . We then analyzed the cellular content of the members of Cip/Kip or the INK4 family of CDKs inhibitors in control and PGRN+ cells. Results are summarized in Fig. 6 . We did not observe differences on either p21 or p27 content between control and PGRN+ cells. Neither we found differences on the INK members, p16 and p18 (Fig. 6 ). Taken together, these observations suggest that the increased pRb phosphorylation in PGRN+ lymphoblasts may depend on CDK6 activity.
To further analyze the involvement of CDK6 activity on the enhanced proliferation of lymphoblasts bearing the c.709-1G>A PGRN mutation, use was made of the CDK6 inhibitor sodium butyrate (Kim et al., 2007) . As shown in Fig. 7A , treatment of PGRN+ lymphoblasts with increasing concentrations of sodium butyrate resulted in a significant inhibition of cell proliferation in a dose-dependent manner. Sodium butyrate did not change the proliferation of lymphoblasts from control individuals. We next evaluated the effect of 10M sodium butyrate on the cellular levels of CDK6. As shown in Fig.7B , treatment of PGRN+ cells with sodium butyrate decreased the content of the CDK6 protein to levels similar to those of control cells. As expected, sodium butyrate was able to decrease the phosphorylation status of pRb in lymphoblasts from PGRN+ subjects (Fig.7B ).
Subcellular distribution of T DP-43.
It has been recently reported that TDP-43, the main protein in the ubiquitin+ inclusions predominantly localizes in the nucleus (Fig. 8A) , although low levels of TDP-43 are observed in the cytosol. The western blot analysis of nuclear and cytoplasmic proteins reveled in PGRN+ cells, a small, but statistically significant, increase in the cytosolic content of TDP-43 that paralleled the decrease in nuclear levels of TDP-43 (Fig. 8B ).
D ISC USSI O N
Accumulating evidence suggests that activation of cell cycle machinery contributes to neuronal dysfunction, and eventual neurodegeneration (Wishart et al., 2006) . A cohort of neurodegenerative conditions that present cell cycle alterations have been identified.
These include AD, PD, ALS and others (Appert-Collin et al., 2006; Hoglinger et al., 2007) . So far, cell cycle disturbances associated with FTLD have been reported for a number of FTLD-tau cases, including carriers of tau mutations or patients bearing tau inclusions (Husseman et al., 2000) . Since these disorders are triggered by different etiologic factors, it is suggested that cell cycle activation may be the cellular response to different insults, and alterations of cell cycle regulatory proteins could be a convergent mechanism to neurodegeneration. Previous work from our and other laboratories (Bartolome et al., 2007; de las Cuevas et al., 2005; de las Cuevas et al., 2003; Muñoz et al., 2008; Nagy et al., 2002; Zhou and Jia, 2010) had demonstrated that cell cyclerelated events can be detected outside the central nervous system i.e. in peripheral blood lymphocytes, suggesting, therefore, that these easily accessible cells may represent useful tools to study the mechanisms involved in the pathogenesis of neurodegenerative diseases.
In this study, we have examined the cellular response to serum stimulation of lymphoblasts derived from control and individuals carrying the c.709-1G>A PGRN mutation, either asymptomatic or diagnosed of FTLD. For this purpose, a comparative study on cell proliferation, cell cycle profiles, and expression levels of key cell cycle regulatory proteins was performed. In addition, we investigated potential differences in the subcellular distribution of TDP-43 in control or PGRN+ lymphoblasts.
Lymphoblasts from PGRN+ subjects show cell cycle progress modifications such as a decrease of cells in G 1 , an increased number of cells in S, together with altered expression and phosphorylation of pRb and other proteins involved in cell cycle regulation. pRb protein functions as a molecular interface coupling the extracellular signals to the transcriptional machinery of the cells (Hatakeyama and Weinberg, 1995) .
When it is hypophosphorylated, pRb forms inhibitory complexes with members of E2F family of transcription factors (Chellappan et al., 1991) . Upon phosphorylation, pRb releases E2F, allowing them to promote the transcription of gene products necessary for cell cycle progression (Helin, 1998) .
pRb is sequentially phosphorylated by two sets of protein kinases, the cyclin D/CDK4/CDK6 and cyclin E/CDK2 complexes (Mittnacht, 1998) . We did not observe differences in the levels of expression of cyclins D and E or in the kinases CDK4 and CDK2 between control and PGRN+ cells. However, a significant increase in cellular content in CDK6 protein was observed in PGRN+ lymphoblasts from FTLD patients. 
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R E F E R E N C ES
Immortalized lymphoblasts from control and PGRN mutation carriers, either asymptomatic or FTLD patients, were seeded at an initial density of 1 x 10 6 ml -1 and cultured in RPMI medium containing 10% FBS. After 2 days of culture, cells were harvested and pRb was detected by immunobloting using a phospho-specific anti-pRb antibody. Two different experiments are shown. pp = the hyperphosphorylated form of the Rb protein.
C ellular content of the C yclin family of proteins involved in G1 regulation in serum-stimulate lymphoblasts from control or P G R N mutation car riers Cells were seeded at an initial density of 1 x 10 6 x ml -1 . Two days after stimulation with 10% FBS, samples were taken from each culture and total cellular proteins were separated on denaturing gels and immunobloted with the appropriate antibody as shown in the figure. Immunoreactive proteins were visualized with the enhanced chemiluminiscence detection system. The densitometric data represent the meanSE for of at least 6 independent experiments carried out in cell lines derived from different individuals. 
